Case and Research Letter
Ustekinumab for Hidradenitis Suppurativa: A Case Report
Ustekinumab en hidradenitis supurativa: a propósito de un caso
Read
11418
Timeswas read the article
2512
Total PDF
8906
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 26 | 3 | 29 |
| 2025 5 | 207 | 32 | 239 |
| 2025 4 | 220 | 24 | 244 |
| 2025 3 | 188 | 15 | 203 |
| 2025 2 | 165 | 29 | 194 |
| 2025 1 | 107 | 32 | 139 |
| 2024 12 | 145 | 20 | 165 |
| 2024 11 | 118 | 70 | 188 |
| 2024 10 | 106 | 40 | 146 |
| 2024 9 | 87 | 72 | 159 |
| 2024 8 | 111 | 50 | 161 |
| 2024 7 | 98 | 42 | 140 |
| 2024 6 | 109 | 41 | 150 |
| 2024 5 | 104 | 36 | 140 |
| 2024 4 | 99 | 21 | 120 |
| 2024 3 | 118 | 34 | 152 |
| 2024 2 | 103 | 33 | 136 |
| 2024 1 | 93 | 40 | 133 |
| 2023 12 | 181 | 47 | 228 |
| 2023 11 | 180 | 37 | 217 |
| 2023 10 | 125 | 23 | 148 |
| 2023 9 | 104 | 25 | 129 |
| 2023 8 | 81 | 28 | 109 |
| 2023 7 | 95 | 32 | 127 |
| 2023 6 | 89 | 27 | 116 |
| 2023 5 | 103 | 25 | 128 |
| 2023 4 | 191 | 24 | 215 |
| 2023 3 | 128 | 63 | 191 |
| 2023 2 | 119 | 25 | 144 |
| 2023 1 | 127 | 23 | 150 |
| 2022 12 | 152 | 40 | 192 |
| 2022 11 | 92 | 30 | 122 |
| 2022 10 | 84 | 22 | 106 |
| 2022 9 | 126 | 42 | 168 |
| 2022 8 | 62 | 40 | 102 |
| 2022 7 | 80 | 31 | 111 |
| 2022 6 | 85 | 22 | 107 |
| 2022 5 | 113 | 30 | 143 |
| 2022 4 | 162 | 36 | 198 |
| 2022 3 | 141 | 39 | 180 |
| 2022 2 | 144 | 25 | 169 |
| 2022 1 | 219 | 46 | 265 |
| 2021 12 | 131 | 31 | 162 |
| 2021 11 | 120 | 42 | 162 |
| 2021 10 | 208 | 50 | 258 |
| 2021 9 | 299 | 48 | 347 |
| 2021 8 | 121 | 35 | 156 |
| 2021 7 | 82 | 27 | 109 |
| 2021 6 | 116 | 34 | 150 |
| 2021 5 | 101 | 47 | 148 |
| 2021 4 | 426 | 63 | 489 |
| 2021 3 | 155 | 24 | 179 |
| 2021 2 | 95 | 30 | 125 |
| 2021 1 | 57 | 15 | 72 |
| 2020 12 | 54 | 18 | 72 |
| 2020 11 | 44 | 9 | 53 |
| 2020 10 | 39 | 8 | 47 |
| 2020 9 | 29 | 16 | 45 |
| 2020 8 | 33 | 22 | 55 |
| 2020 7 | 38 | 17 | 55 |
| 2020 6 | 58 | 21 | 79 |
| 2020 5 | 39 | 19 | 58 |
| 2020 4 | 39 | 11 | 50 |
| 2020 3 | 28 | 15 | 43 |
| 2020 2 | 6 | 1 | 7 |
| 2020 1 | 0 | 3 | 3 |
| 2019 12 | 4 | 5 | 9 |
| 2019 11 | 0 | 1 | 1 |
| 2019 9 | 4 | 0 | 4 |
| 2019 8 | 0 | 1 | 1 |
| 2019 7 | 0 | 1 | 1 |
| 2019 6 | 3 | 12 | 15 |
| 2019 5 | 0 | 11 | 11 |
| 2019 4 | 0 | 1 | 1 |
| 2019 3 | 2 | 6 | 8 |
| 2019 1 | 2 | 0 | 2 |
| 2018 12 | 1 | 0 | 1 |
| 2018 11 | 1 | 0 | 1 |
| 2018 10 | 3 | 0 | 3 |
| 2018 9 | 6 | 0 | 6 |
| 2018 8 | 0 | 1 | 1 |
| 2018 6 | 0 | 2 | 2 |
| 2018 5 | 0 | 3 | 3 |
| 2018 3 | 1 | 2 | 3 |
| 2018 2 | 49 | 9 | 58 |
| 2018 1 | 75 | 9 | 84 |
| 2017 12 | 76 | 9 | 85 |
| 2017 11 | 53 | 13 | 66 |
| 2017 10 | 40 | 4 | 44 |
| 2017 9 | 36 | 14 | 50 |
| 2017 8 | 55 | 16 | 71 |
| 2017 7 | 54 | 14 | 68 |
| 2017 6 | 47 | 15 | 62 |
| 2017 5 | 51 | 25 | 76 |
| 2017 4 | 42 | 10 | 52 |
| 2017 3 | 32 | 43 | 75 |
| 2017 2 | 26 | 9 | 35 |
| 2017 1 | 36 | 13 | 49 |
| 2016 12 | 48 | 13 | 61 |
| 2016 11 | 44 | 13 | 57 |
| 2016 10 | 64 | 13 | 77 |
| 2016 9 | 62 | 7 | 69 |
| 2016 8 | 1 | 3 | 4 |
| 2016 7 | 8 | 7 | 15 |
| 2016 6 | 15 | 3 | 18 |
| 2016 5 | 11 | 3 | 14 |
| 2016 4 | 9 | 51 | 60 |
| 2016 3 | 11 | 4 | 15 |
| 2016 2 | 12 | 1 | 13 |
| 2016 1 | 12 | 7 | 19 |
| 2015 12 | 13 | 2 | 15 |
| 2015 11 | 13 | 0 | 13 |
| 2015 10 | 16 | 6 | 22 |
| 2015 9 | 6 | 6 | 12 |
| 2015 8 | 20 | 5 | 25 |
| 2015 7 | 54 | 9 | 63 |
| 2015 6 | 42 | 8 | 50 |
| 2015 5 | 49 | 15 | 64 |
| 2015 4 | 32 | 11 | 43 |
| 2015 3 | 28 | 5 | 33 |
| 2015 2 | 33 | 8 | 41 |
| 2015 1 | 13 | 5 | 18 |
| 2014 12 | 26 | 9 | 35 |
| 2014 11 | 19 | 10 | 29 |
| 2014 10 | 25 | 10 | 35 |
| 2014 9 | 16 | 7 | 23 |
Show all
